Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

NCT05955157 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Advanced Solid Tumor

Interventions

BIOLOGICAL: Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
DRUG: Tegafur Only Product

Sponsor

University of Malaya